Abstract
Botulinum toxin A (BTX-A) has long been used for the management of the sequelae of facial paralysis and other neuromuscular conditions. Evidence is limited in its efficacy and outcomes, and there is a lack of standardisation in its use. Both objective and subjective outcomes in BTX-A injections for facial paralysis are favourable. Differences are seen depending on type of botulinum toxin used, but most studies recommend OnabotulinumtoxinA. BTX-A injection is an effective method in the treatment of these disorders, improving patient outcomes through a minimally invasive approach. There is however a paucity of randomised control trials and standardisation of protocols of its use.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
